Hickory Asset Management Inc. Sells 86 Shares of Cencora, Inc. (NYSE:COR)

Hickory Asset Management Inc. cut its holdings in Cencora, Inc. (NYSE:COR) by 3.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,462 shares of the company’s stock after selling 86 shares during the quarter. Hickory Asset Management Inc.’s holdings in Cencora were worth $685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of COR. JFS Wealth Advisors LLC boosted its position in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new stake in Cencora during the 4th quarter valued at approximately $29,000. SBI Securities Co. Ltd. bought a new stake in Cencora during the 4th quarter valued at approximately $30,000. WASHINGTON TRUST Co boosted its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. Finally, Vermillion Wealth Management Inc. purchased a new position in shares of Cencora during the fourth quarter valued at approximately $38,000. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the business’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares of the company’s stock, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company’s stock, valued at approximately $85,680,732.63. The trade was a 4.38% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,253 shares of company stock worth $10,582,297. Insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $295.12 on Friday. The firm has a market cap of $57.20 billion, a PE ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a fifty day simple moving average of $287.24 and a two-hundred day simple moving average of $261.65. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $3.80 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. Cencora’s dividend payout ratio is presently 25.52%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on COR shares. Citigroup lifted their target price on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. Wells Fargo & Company upgraded shares of Cencora from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. UBS Group lifted their target price on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Finally, Bank of America lifted their target price on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.